The article discusses various analyst ratings for Y-mAbs Therapeutics, showing a mix of bullish and somewhat bullish sentiments, with a slight decrease in average price targets. The company's financial metrics are strong, but its revenue growth is slower than its peers, which may neutralize the impact of the mixed ratings.